866-997-4948(US-Canada Toll Free)

Ovarian Cancer - Pipeline Review, H2 2014

Published By :

Global Markets Direct

Published Date : Oct 2014

Category :

Ovarian Cancer

No. of Pages : 1100 Pages

Ovarian Cancer - Pipeline Review, H2 2014

Summary

Global Markets Directs, Ovarian Cancer - Pipeline Review, H2 2014, provides an overview of the Ovarian Cancers therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ovarian Cancer and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Ovarian Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Ovarian Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Ovarian Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Ovarian Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Ovarian Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Ovarian Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
Introduction 10
Ovarian Cancer Overview 11
Therapeutics Development 12
Ovarian Cancer - Therapeutics under Development by Companies 14
Ovarian Cancer - Therapeutics under Investigation by Universities/Institutes 30
Ovarian Cancer - Pipeline Products Glance 34
Ovarian Cancer - Products under Development by Companies 38
Ovarian Cancer - Products under Investigation by Universities/Institutes 58
Ovarian Cancer - Companies Involved in Therapeutics Development 61
Ovarian Cancer - Therapeutics Assessment 252
Drug Profiles 281
Ovarian Cancer - Recent Pipeline Updates 816
Ovarian Cancer - Dormant Projects 1048
Ovarian Cancer - Discontinued Products 1055
Ovarian Cancer - Product Development Milestones 1057
Appendix 1063

List of Tables
Number of Products under Development for Ovarian Cancer, H2 2014 48
Number of Products under Development for Ovarian Cancer - Comparative Analysis, H2 2014 49
Number of Products under Development by Companies, H2 2014 51
Number of Products under Development by Companies, H2 2014 (Contd..1) 52
Number of Products under Development by Companies, H2 2014 (Contd..2) 53
Number of Products under Development by Companies, H2 2014 (Contd..3) 54
Number of Products under Development by Companies, H2 2014 (Contd..4) 55
Number of Products under Development by Companies, H2 2014 (Contd..5) 56
Number of Products under Development by Companies, H2 2014 (Contd..6) 57
Number of Products under Development by Companies, H2 2014 (Contd..7) 58
Number of Products under Development by Companies, H2 2014 (Contd..8) 59
Number of Products under Development by Companies, H2 2014 (Contd..9) 60
Number of Products under Development by Companies, H2 2014 (Contd..10) 61
Number of Products under Development by Companies, H2 2014 (Contd..11) 62
Number of Products under Development by Companies, H2 2014 (Contd..12) 63
Number of Products under Development by Companies, H2 2014 (Contd..13) 64
Number of Products under Development by Companies, H2 2014 (Contd..14) 65
Number of Products under Investigation by Universities/Institutes, H2 2014 67
Number of Products under Investigation by Universities/Institutes, H2 2014 (Contd..1) 68
Number of Products under Investigation by Universities/Institutes, H2 2014 (Contd..2) 69
Comparative Analysis by Late Stage Development, H2 2014 70
Comparative Analysis by Clinical Stage Development, H2 2014 71
Comparative Analysis by Early Stage Development, H2 2014 72
Comparative Analysis by Unknown Stage Development, H2 2014 73
Products under Development by Companies, H2 2014 74
Products under Development by Companies, H2 2014 (Contd..1) 75
Products under Development by Companies, H2 2014 (Contd..2) 76
Products under Development by Companies, H2 2014 (Contd..3) 77
Products under Development by Companies, H2 2014 (Contd..4) 78
Products under Development by Companies, H2 2014 (Contd..5) 79
Products under Development by Companies, H2 2014 (Contd..6) 80
Products under Development by Companies, H2 2014 (Contd..7) 81
Products under Development by Companies, H2 2014 (Contd..8) 82
Products under Development by Companies, H2 2014 (Contd..9) 83
Products under Development by Companies, H2 2014 (Contd..10) 84
Products under Development by Companies, H2 2014 (Contd..11) 85
Products under Development by Companies, H2 2014 (Contd..12) 86
Products under Development by Companies, H2 2014 (Contd..13) 87
Products under Development by Companies, H2 2014 (Contd..14) 88
Products under Development by Companies, H2 2014 (Contd..15) 89
Products under Development by Companies, H2 2014 (Contd..16) 90
Products under Development by Companies, H2 2014 (Contd..17) 91
Products under Development by Companies, H2 2014 (Contd..18) 92
Products under Development by Companies, H2 2014 (Contd..19) 93
Products under Investigation by Universities/Institutes, H2 2014 94
Products under Investigation by Universities/Institutes, H2 2014 (Contd..1) 95
Products under Investigation by Universities/Institutes, H2 2014 (Contd..2) 96
Ovarian Cancer - Pipeline by 3-V Biosciences, Inc., H2 2014 97
Ovarian Cancer - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2014 98
Ovarian Cancer - Pipeline by AbbVie Inc., H2 2014 99
Ovarian Cancer - Pipeline by AbGenomics International, Inc., H2 2014 100
Ovarian Cancer - Pipeline by Acceleron Pharma, Inc., H2 2014 101
Ovarian Cancer - Pipeline by Adocia, H2 2014 102
Ovarian Cancer - Pipeline by Aduro BioTech, Inc., H2 2014 103
Ovarian Cancer - Pipeline by Advanced Accelerator Applications SA, H2 2014 104
Ovarian Cancer - Pipeline by Advantagene, Inc., H2 2014 105
Ovarian Cancer - Pipeline by Advaxis, Inc., H2 2014 106
Ovarian Cancer - Pipeline by Advenchen Laboratories, LLC, H2 2014 107
Ovarian Cancer - Pipeline by Aeterna Zentaris Inc., H2 2014 108
Ovarian Cancer - Pipeline by Alethia Biotherapeutics Inc., H2 2014 109
Ovarian Cancer - Pipeline by Almac Discovery Ltd., H2 2014 110
Ovarian Cancer - Pipeline by Ambrx, Inc., H2 2014 111
Ovarian Cancer - Pipeline by Amgen Inc., H2 2014 112
Ovarian Cancer - Pipeline by Amorfix Life Sciences Ltd., H2 2014 113
Ovarian Cancer - Pipeline by Angstrom Pharmaceuticals, Inc., H2 2014 114
Ovarian Cancer - Pipeline by AntiCancer, Inc., H2 2014 115
Ovarian Cancer - Pipeline by Aphios Corporation, H2 2014 116
Ovarian Cancer - Pipeline by Aposense Ltd., H2 2014 117
Ovarian Cancer - Pipeline by Aprea AB, H2 2014 118
Ovarian Cancer - Pipeline by arGEN-X BV, H2 2014 119
Ovarian Cancer - Pipeline by Armour Therapeutics Inc., H2 2014 120
Ovarian Cancer - Pipeline by Arrien Pharmaceuticals, LLC, H2 2014 121
Ovarian Cancer - Pipeline by Ascenta Therapeutics, Inc., H2 2014 122
Ovarian Cancer - Pipeline by Ascentage Pharma Group Corporation, Ltd., H2 2014 123
Ovarian Cancer - Pipeline by Astellas Pharma Inc., H2 2014 124
Ovarian Cancer - Pipeline by AstraZeneca PLC, H2 2014 125
Ovarian Cancer - Pipeline by Atara Biotherapeutics, Inc., H2 2014 126
Ovarian Cancer - Pipeline by AVAX Technologies, Inc., H2 2014 127
Ovarian Cancer - Pipeline by Avipep Pty Ltd, H2 2014 128
Ovarian Cancer - Pipeline by Azaya Therapeutics Incorporated, H2 2014 129
Ovarian Cancer - Pipeline by Basilea Pharmaceutica AG, H2 2014 130
Ovarian Cancer - Pipeline by Bavarian Nordic A/S, H2 2014 131
Ovarian Cancer - Pipeline by BioCancell Therapeutics, Inc., H2 2014 132
Ovarian Cancer - Pipeline by BioMarin Pharmaceutical Inc., H2 2014 133
Ovarian Cancer - Pipeline by BioMoti Limited, H2 2014 134
Ovarian Cancer - Pipeline by Bionomics Limited, H2 2014 135
Ovarian Cancer - Pipeline by Bioo Therapeutics, H2 2014 136
Ovarian Cancer - Pipeline by BiOrion Technologies B.V., H2 2014 137
Ovarian Cancer - Pipeline by Biscayne Pharmaceuticals, Inc., H2 2014 138
Ovarian Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2014 139
Ovarian Cancer - Pipeline by Bolder Biotechnology, Inc., H2 2014 140
Ovarian Cancer - Pipeline by Boston Biomedical, Inc., H2 2014 141
Ovarian Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2014 142
Ovarian Cancer - Pipeline by CanBas Co., Ltd., H2 2014 143
Ovarian Cancer - Pipeline by CASI Pharmaceuticals Inc., H2 2014 144
Ovarian Cancer - Pipeline by Cavion LLC, H2 2014 145
Ovarian Cancer - Pipeline by Celgene Corporation, H2 2014 146
Ovarian Cancer - Pipeline by Celldex Therapeutics, Inc., H2 2014 147
Ovarian Cancer - Pipeline by Ceronco Biosciences, H2 2014 148
Ovarian Cancer - Pipeline by Cerulean Pharma, Inc., H2 2014 149
Ovarian Cancer - Pipeline by Chikujee Therapeutics, H2 2014 150
Ovarian Cancer - Pipeline by Chipscreen Biosciences Ltd, H2 2014 151
Ovarian Cancer - Pipeline by Cold Genesys, Inc., H2 2014 152
Ovarian Cancer - Pipeline by Coronado Biosciences, Inc., H2 2014 153
Ovarian Cancer - Pipeline by Critical Outcome Technologies Inc., H2 2014 154
Ovarian Cancer - Pipeline by CritiTech, Inc., H2 2014 155
Ovarian Cancer - Pipeline by CTI BioPharma Corp., H2 2014 156
Ovarian Cancer - Pipeline by Curis, Inc., H2 2014 157
Ovarian Cancer - Pipeline by Cyclacel Pharmaceuticals, Inc., H2 2014 158
Ovarian Cancer - Pipeline by CytRx Corporation, H2 2014 159
Ovarian Cancer - Pipeline by CZ BioMed Corp, H2 2014 160
Ovarian Cancer - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 161
Ovarian Cancer - Pipeline by Deciphera Pharmaceuticals, LLC, H2 2014 162
Ovarian Cancer - Pipeline by DEKK-TEC, Inc., H2 2014 163
Ovarian Cancer - Pipeline by Dendreon Corporation, H2 2014 164
Ovarian Cancer - Pipeline by Eli Lilly and Company, H2 2014 165
Ovarian Cancer - Pipeline by Endocyte, Inc., H2 2014 166
Ovarian Cancer - Pipeline by Erytech Pharma SA, H2 2014 167
Ovarian Cancer - Pipeline by Esperance Pharmaceuticals, Inc., H2 2014 168
Ovarian Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 169
Ovarian Cancer - Pipeline by Formula Pharmaceuticals, Inc., H2 2014 170
Ovarian Cancer - Pipeline by Fujifilm Corporation, H2 2014 171
Ovarian Cancer - Pipeline by Galena Biopharma, Inc., H2 2014 172
Ovarian Cancer - Pipeline by Galileo Research s.r.l., H2 2014 173
Ovarian Cancer - Pipeline by GamaMabs Pharma S.A., H2 2014 174
Ovarian Cancer - Pipeline by Ganymed Pharmaceuticals AG, H2 2014 175
Ovarian Cancer - Pipeline by Genentech, Inc., H2 2014 176
Ovarian Cancer - Pipeline by Generex Biotechnology Corporation, H2 2014 177
Ovarian Cancer - Pipeline by Genmab A/S, H2 2014 178
Ovarian Cancer - Pipeline by GlaxoSmithKline plc, H2 2014 179
Ovarian Cancer - Pipeline by GlycoNex Inc., H2 2014 180
Ovarian Cancer - Pipeline by GP Pharm, S.A., H2 2014 181
Ovarian Cancer - Pipeline by Gradalis Inc., H2 2014 182
Ovarian Cancer - Pipeline by Heat Biologics, Inc., H2 2014 183
Ovarian Cancer - Pipeline by Hemispherx Biopharma, Inc., H2 2014 184
Ovarian Cancer - Pipeline by Huabo Biopharm Co., Ltd., H2 2014 185
Ovarian Cancer - Pipeline by Ildong Pharmaceutical Co., Ltd., H2 2014 186
Ovarian Cancer - Pipeline by IMMD Inc., H2 2014 187
Ovarian Cancer - Pipeline by ImmunoCellular Therapeutics, Ltd., H2 2014 188
Ovarian Cancer - Pipeline by Immunomedics, Inc., H2 2014 189
Ovarian Cancer - Pipeline by Immunovaccine, Inc., H2 2014 190
Ovarian Cancer - Pipeline by Immunovative Therapies, Ltd., H2 2014 191
Ovarian Cancer - Pipeline by Innate Pharma SA, H2 2014 192
Ovarian Cancer - Pipeline by Innate Therapeutics Limited, H2 2014 193
Ovarian Cancer - Pipeline by INSYS Therapeutics, Inc., H2 2014 194
Ovarian Cancer - Pipeline by ISA Pharmaceuticals B.V., H2 2014 195
Ovarian Cancer - Pipeline by iTeos Therapeutics SA, H2 2014 196
Ovarian Cancer - Pipeline by Jiangsu Kanion Pharmaceutical Co., Ltd., H2 2014 197
Ovarian Cancer - Pipeline by Karyopharm Therapeutics, Inc., H2 2014 198
Ovarian Cancer - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2014 199
Ovarian Cancer - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2014 200
Ovarian Cancer - Pipeline by Mebiopharm Co., Ltd., H2 2014 201
Ovarian Cancer - Pipeline by Medestea Research & Production S.p.A., H2 2014 202
Ovarian Cancer - Pipeline by MedImmune, LLC, H2 2014 203
Ovarian Cancer - Pipeline by MEI Pharma, Inc., H2 2014 204
Ovarian Cancer - Pipeline by Merck & Co., Inc., H2 2014 205
Ovarian Cancer - Pipeline by Merck KGaA, H2 2014 206
Ovarian Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2014 207
Ovarian Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H2 2014 208
Ovarian Cancer - Pipeline by Mission Therapeutics Ltd, H2 2014 209
Ovarian Cancer - Pipeline by MolMed S.p.A., H2 2014 210
Ovarian Cancer - Pipeline by Morphotek, Inc., H2 2014 211
Ovarian Cancer - Pipeline by Natco Pharma Limited, H2 2014 212
Ovarian Cancer - Pipeline by Nektar Therapeutics, H2 2014 213
Ovarian Cancer - Pipeline by Nemucore Medical Innovations, Inc., H2 2014 214
Ovarian Cancer - Pipeline by Neopharm Ltd., H2 2014 215
Ovarian Cancer - Pipeline by Neotropix, Inc., H2 2014 216
Ovarian Cancer - Pipeline by Nerviano Medical Sciences, H2 2014 217
Ovarian Cancer - Pipeline by NewLink Genetics Corporation, H2 2014 218
Ovarian Cancer - Pipeline by Novartis AG, H2 2014 219
Ovarian Cancer - Pipeline by Novogen Limited, H2 2014 220
Ovarian Cancer - Pipeline by NuCana BioMed Limited, H2 2014 221
Ovarian Cancer - Pipeline by Oasmia Pharmaceutical AB, H2 2014 222
Ovarian Cancer - Pipeline by Ohr Pharmaceutical Inc., H2 2014 223
Ovarian Cancer - Pipeline by Omeros Corporation, H2 2014 224
Ovarian Cancer - Pipeline by Omnitura Therapeutics Inc., H2 2014 225
Ovarian Cancer - Pipeline by Oncodesign SA, H2 2014 226
Ovarian Cancer - Pipeline by Oncogenex Pharmaceuticals, Inc., H2 2014 227
Ovarian Cancer - Pipeline by OncoHoldings, Inc., H2 2014 228
Ovarian Cancer - Pipeline by Oncolix, Inc., H2 2014 229
Ovarian Cancer - Pipeline by Oncology Research International Limited, H2 2014 230
Ovarian Cancer - Pipeline by Oncolytics Biotech Inc., H2 2014 231
Ovarian Cancer - Pipeline by OncoMed Pharmaceuticals, Inc., H2 2014 232
Ovarian Cancer - Pipeline by Oncos Therapeutics Ltd., H2 2014 233
Ovarian Cancer - Pipeline by Oncothyreon Inc., H2 2014 234
Ovarian Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2014 235
Ovarian Cancer - Pipeline by Onyx Pharmaceuticals, Inc., H2 2014 236
Ovarian Cancer - Pipeline by Optimum Therapeutics, LLC, H2 2014 237
Ovarian Cancer - Pipeline by ORCA Therapeutics B.V., H2 2014 238
Ovarian Cancer - Pipeline by OSE Pharma SA, H2 2014 239
Ovarian Cancer - Pipeline by Oxford BioTherapeutics Ltd, H2 2014 240
Ovarian Cancer - Pipeline by OXiGENE, Inc., H2 2014 241
Ovarian Cancer - Pipeline by Panacela Labs, Inc., H2 2014 242
Ovarian Cancer - Pipeline by Pantarhei Bioscience BV, H2 2014 243
Ovarian Cancer - Pipeline by Pfizer Inc., H2 2014 244
Ovarian Cancer - Pipeline by Pharma Mar, S.A., H2 2014 245
Ovarian Cancer - Pipeline by Pharmicell Co., Ltd., H2 2014 246
Ovarian Cancer - Pipeline by PlasmaTech Biopharmaceuticals, Inc., H2 2014 247
Ovarian Cancer - Pipeline by Polaris Group, H2 2014 248
Ovarian Cancer - Pipeline by Pono Pharma, H2 2014 249
Ovarian Cancer - Pipeline by Precision Biologics, Inc., H2 2014 250
Ovarian Cancer - Pipeline by Qu Biologics Inc., H2 2014 251
Ovarian Cancer - Pipeline by Quest PharmaTech Inc., H2 2014 252
Ovarian Cancer - Pipeline by Quintessence Biosciences, Inc., H2 2014 253
Ovarian Cancer - Pipeline by RAPID Pharmaceuticals AG, H2 2014 254
Ovarian Cancer - Pipeline by Recepta Biopharma S.A., H2 2014 255
Ovarian Cancer - Pipeline by Rexahn Pharmaceuticals, Inc., H2 2014 256
Ovarian Cancer - Pipeline by Rosetta Genomics, Ltd., H2 2014 257
Ovarian Cancer - Pipeline by Sanofi, H2 2014 258
Ovarian Cancer - Pipeline by Santaris Pharma A/S, H2 2014 259
Ovarian Cancer - Pipeline by Scancell Holdings Plc, H2 2014 260
Ovarian Cancer - Pipeline by Sellas Inc., H2 2014 261
Ovarian Cancer - Pipeline by SentoClone International AB, H2 2014 262
Ovarian Cancer - Pipeline by Serina Therapeutics, Inc., H2 2014 263
Ovarian Cancer - Pipeline by Soricimed Biopharma Inc., H2 2014 264
Ovarian Cancer - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2014 265
Ovarian Cancer - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2014 266
Ovarian Cancer - Pipeline by Sunesis Pharmaceuticals, Inc., H2 2014 267
Ovarian Cancer - Pipeline by Supratek Pharma Inc., H2 2014 268
Ovarian Cancer - Pipeline by Synta Pharmaceuticals Corp., H2 2014 269
Ovarian Cancer - Pipeline by Tactic Pharma, LLC, H2 2014 270
Ovarian Cancer - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 271
Ovarian Cancer - Pipeline by TapImmune Inc., H2 2014 272
Ovarian Cancer - Pipeline by Telik, Inc., H2 2014 273
Ovarian Cancer - Pipeline by Tesaro, Inc., H2 2014 274
Ovarian Cancer - Pipeline by TRACON Pharmaceuticals, Inc., H2 2014 275
Ovarian Cancer - Pipeline by Trojantec ltd., H2 2014 276
Ovarian Cancer - Pipeline by TVAX Biomedical, Inc., H2 2014 277
Ovarian Cancer - Pipeline by ValiRx Plc, H2 2014 278
Ovarian Cancer - Pipeline by Vascular Biogenics Ltd., H2 2014 279
Ovarian Cancer - Pipeline by Vaxeal Holding SA, H2 2014 280
Ovarian Cancer - Pipeline by Verastem, Inc., H2 2014 281
Ovarian Cancer - Pipeline by ViraTherapeutics GmbH, H2 2014 282
Ovarian Cancer - Pipeline by Viventia Biotechnologies Inc., H2 2014 283
Ovarian Cancer - Pipeline by Welichem Biotech Inc., H2 2014 284
Ovarian Cancer - Pipeline by Zensun (Shanghai) Sci & Tech Co., Ltd., H2 2014 285
Ovarian Cancer - Pipeline by ZIOPHARM Oncology, Inc., H2 2014 286
Ovarian Cancer - Pipeline by Zymeworks Inc., H2 2014 287
Assessment by Monotherapy Products, H2 2014 288
Assessment by Combination Products, H2 2014 289
Number of Products by Stage and Target, H2 2014 291
Number of Products by Stage and Mechanism of Action, H2 2014 305
Number of Products by Stage and Route of Administration, H2 2014 314
Number of Products by Stage and Molecule Type, H2 2014 316
Ovarian Cancer Therapeutics - Recent Pipeline Updates, H2 2014 852
Ovarian Cancer - Dormant Projects, H2 2014 1084
Ovarian Cancer - Discontinued Products, H2 2014 1091

List of Figures
Number of Products under Development for Ovarian Cancer, H2 2014 48
Number of Products under Development for Ovarian Cancer - Comparative Analysis, H2 2014 49
Number of Products under Development by Companies, H2 2014 50
Number of Products under Investigation by Universities/Institutes, H2 2014 66
Comparative Analysis by Late Stage Development, H2 2014 70
Comparative Analysis by Clinical Stage Development, H2 2014 71
Comparative Analysis by Early Stage Products, H2 2014 72
Assessment by Monotherapy Products, H2 2014 288
Assessment by Combination Products, H2 2014 289
Number of Products by Top 10 Targets, H2 2014 290
Number of Products by Stage and Top 10 Targets, H2 2014 290
Number of Products by Top 10 Mechanism of Actions, H2 2014 304
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 304
Number of Products by Top 10 Routes of Administration, H2 2014 313
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 313
Number of Products by Top 10 Molecule Types, H2 2014 315
Number of Products by Stage and Top 10 Molecule Types, H2 2014 315

List of Table

NA

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *